LANTUS® long-acting (basal) insulin delivers effective glycemic control in diabetes
patients as part of an overall diabetes treatment plan, which includes diet, exercise
and other diabetes medications.
An appropriate dose and proper titration are necessary for glycemic goal attainment.
From data on file.1,3,4
- Associated with a low rate of hypoglycemia1
- Study designed to compare safety and efficacy of LANTUS®, long-acting (basal) insulin and NPH
insulin3
In a 52-week study 570 patients with type 2 diabetes poorly controlled
by oral diabetes medications (OADs) were randomized to either LANTUS® (n=289)
or NPH (n=281) at bedtime to reach a target blood glucose of 120 mg/dL. OADs were
continued.
From LANTUS® Prescribing Information1 and data on file.3
- 0.5% mean A1C reduction at 52 weeks3
IMPORTANT SAFETY INFORMATION FOR LANTUS®
LANTUS® is indicated for once-daily subcutaneous administration, at the same
time each day, for the treatment of adult and pediatric patients (6 years and older)
with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who
require basal (long-acting) insulin for the control of hyperglycemia.
LANTUS® SoloSTAR® is a disposable insulin delivery device. Needles and
the SoloSTAR® pen must not be shared.
LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed
or diluted, the solution may become cloudy, and the onset of action/time to peak
effect may be altered in an unpredictable manner.
LANTUS® is contraindicated in patients hypersensitive to insulin glargine or
the excipients.
Hypoglycemia is the most common adverse effect of insulin, including LANTUS®.
As with all insulins, the timing of hypoglycemia may differ among various insulin
formulations. Glucose monitoring is recommended for all patients with diabetes.
Any change of insulin type and/or regimen should be made cautiously and only under
medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted.
Other adverse events commonly associated with LANTUS® include the following:
lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash),
and allergic reactions.
In clinical studies in adult patients there was a higher incidence of treatment-emergent
injection-site pain (2.7% LANTUS® vs 0.7% NPH). The reports of pain at the injection
site were usually mild and did not result in discontinuation of therapy.
Please click here for full prescribing information.
